Publication | Closed Access

VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

OncologyHepatologyMedicineFirst-line Systemic TreatmentPathologyPharmacotherapyVersus SorafenibLiver CancerCancer TreatmentPharmacologyRadiation OncologyHepatocellular CarcinomaAdvanced Hepatocellular Carcinoma